1	IL-6 trans-signaling mediates cytokine secretion and barrier dysfunction in		
2	hantavirus infected cells and correlate to severity in HFRS		
3			
4	Kimia T. Maleki ^{a,e} , Linda Niemetz ^{a,b,e} , Wanda Christ ^a , Julia Wigren Byström ^c , Therese		
5	Thunberg ^c , Clas Ahlm ^c , Jonas Klingström ^{a,d,*}		
6			
7	Affiliations:		
8	^a Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,		
9	Stockholm, Sweden.		
10	^b Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.		
11	^c Department of Clinical Microbiology, Umeå University, Umeå, Sweden.		
12	^d Division of Molecular Medicine and Virology, Department of Biomedical and Clinical		
13	Sciences, Linköping University, Linköping, Sweden.		
14			
15	^e Both authors contributed equally.		
16			
17	*Corresponding author. Division of Molecular Medicine and Virology, Department of		
18	Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.		
19	E-mail address: Jonas.Klingstrom@liu.se (J. Klingström)		
20			
21	Keywords: IL-6 trans-signaling; IL-6; prognostic biomarkers; Hantavirus; Hemorrhagic fever		
22	with renal syndrome (HFRS); Endothelial cells; Vascular permeability; Inflammation		

23 Abstract

24	Background: Hantavirus causes hemorrhagic fever with renal syndrome (HFRS) and hantavirus
25	pulmonary syndrome (HPS). Strong inflammatory responses and vascular leakage are important
26	hallmarks of these often fatal diseases. The mechanism behind pathogenesis is unknown and no
27	specific treatment is available. IL-6 was recently highlighted as a biomarker for HPS/HFRS
28	severity. IL-6 signaling is complex and context dependent: while classical signaling generally
29	provide protective responses, trans-signaling can cause severe pathogenic responses. This study
30	aims to investigate a potential role for IL-6 trans-signaling in hantavirus pathogenesis.
31	Methods: Effects of IL-6 trans-signaling during in vitro hantavirus infection were assessed using
32	primary human endothelial cells treated with recombinant soluble IL-6 receptor (sIL-6R). Plasma
33	from Puumala orthohantavirus-infected HFRS patients (n=28) were analyzed for IL-6 trans-
34	signaling potential and its associations to severity.
35	Findings: In vitro, sIL-6R treatment of infected cells enhanced IL-6 and CCL2 secretion,
36	upregulated ICAM-1, and affected VE-cadherin leading to a disrupted cell barrier integrity.
37	HFRS patients showed altered plasma levels of sIL-6R and soluble gp130 (sgp130) resulting in
38	an increased sIL-6R/sgp130 ratio suggesting enhanced IL-6 trans-signaling potential. Plasma
39	sgp130 levels negatively correlated with number of interventions and positively with albumin
40	levels. Patients receiving oxygen treatment displayed a higher sIL-6R/sgp130 ratio compared to
41	patients that did not.
42	Interpretation: IL-6 trans-signaling is linked to hantavirus pathogenesis. Targeting IL-6 trans-
43	signaling might provide a therapeutic strategy for treatment of HPS and severe HFRS.

44 Research in context

45 Evidence before this study

IL-6 have dual effects, it provides important antiviral responses but can also cause severe 46 pathogenesis. IL-6 mediated effects are activated by two different mechanisms, classical 47 signaling and trans-signaling. IL-6 trans-signaling have recently been shown to be responsible 48 49 for IL-6 mediated pathogenesis. Endothelial cells lack membrane-bound IL-6 receptor and only respond to IL-6 trans-signaling. Orthohantaviruses cause hemorrhagic fever with renal syndrome 50 (HFRS) and hantavirus pulmonary syndrome (HPS; also called hantavirus cardiopulmonary 51 syndrome (HCPS)), acute severe zoonotic diseases with high fatality rates for which specific 52 treatments and vaccines are lacking. Deregulated vascular permeability and inflammation are 53 hallmarks of HPS and severe HFRS. However, the mechanisms underlying hantavirus disease 54 are unknown, hampering the development of treatments. Orthohantaviruses primarily infect 55 endothelial cells. Previous studies have demonstrated a correlation between elevated IL-6 levels 56 57 and increased severity of HPS and HFRS. Whether this link is causal, and if so the mechanisms behind it, has not been determined. 58

59

60 Added value of this study

This study demonstrates that hantavirus-infected endothelial cells produce large amounts of IL-6, and are highly sensitive to IL-6 trans-signaling mechanisms. Together this strongly amplifies the IL-6 production and disrupt the endothelial cell barrier causing severe fluid leakage. When analyzing a potential role for IL-6 trans-signaling in patients, we observed increased systemic IL-6 trans-signaling potential, and that this was linked to severity, in Puumala virus-infected HFRS patients.

67 Implications of all the available evidence

- 68 These data suggest the two hallmarks of HPS and HFRS; increased vascular permeability and
- 69 strong inflammation, is linked via hantavirus-induced endothelial cell IL-6 production and IL-6
- 70 trans-signaling effects. Treatment targeting IL-6 trans-signaling might provide a therapeutic
- 71 strategy for HPS and severe HFRS.

72 INTRODUCTION

73 Orthohantavirus comprise a genus of single-stranded negative sense RNA viruses.¹

Orthohantaviruses, hereafter referred to as hantaviruses, are transmitted to humans via inhalation 74 of aerosolized virions from rodent excreta. Puumala orthohantavirus (PUUV) is the most 75 prevalent hantavirus species in Europe and causes hemorrhagic fever with renal syndrome 76 (HFRS).² HFRS patients typically present with headache, fever, myalgia and renal symptoms.^{2,3} 77 Fatality rates ranges between 0.4 to around 10%, depending on the specific hantavirus.^{2,3} In the 78 Americas, hantaviruses such as Andes virus (ANDV) cause hantavirus pulmonary syndrome 79 80 (HPS), a disease characterized by influenza-like symptoms and severe pulmonary dysfunction leading to a fatality rate of around 30-40%.³ Lung involvement is also seen in many PUUV-81 infected HFRS patients.⁴ Hantavirus primarily infects endothelial cells, especially in the lungs.² 82 Increased vascular permeability is a prominent hallmark of hantavirus infection, responsible for 83 the life-threatening pulmonary dysfunction in HPS and severe HFRS.² However, the mechanisms 84 behind hantavirus-induced vascular permeability are not known. As hantavirus infected cells are 85 protected from apoptosis,^{5,6} it is likely that other factors than endothelial cell death are involved 86 in the etiology of vascular permeability during hantavirus infection.^{2,3} 87

HFRS and HPS patients commonly exhibit increased systemic levels of pro-inflammatory
cytokines.⁷⁻¹¹ Recently, we and others reported that IL-6 is associated with increased disease
severity in HPS.^{7,12} In addition, we showed that serum IL-6 levels are higher in fatal compared to
non-fatal HPS cases.⁷ In PUUV-caused HFRS, high plasma IL-6 levels have been associated
with high serum creatinine levels, thrombocytopenia and longer hospitalization, suggesting that
IL-6 is associated also to the disease severity of HFRS.¹³ The mechanisms behind the association
between IL-6 and disease severity of hantavirus infections are currently unknown.

95	IL-6 is a pro-inflammatory cytokine with many functions including in eliciting the acute
96	phase response and promoting T cell activation and B cell maturation. ¹⁴ IL-6 signals via a
97	receptor complex constituting of the IL-6 receptor (IL-6R) and gp130. ^{14,15} Classical IL-6
98	signaling is achieved upon binding of IL-6 to membrane bound IL-6R and gp130. ^{14,15} While
99	gp130 is expressed by all cells, IL-6R is expressed mainly by certain immune cells and
100	hepatocytes. Thus, classical IL-6 signaling is restricted only to these IL-6R-expressing cell
101	types. ^{14,15} However, proteolytic cleavage and alternative splicing create soluble IL-6R (sIL-6R)
102	which binds to IL-6 with low affinity. ¹⁶ In turn, the soluble IL-6:sIL-6R complex can bind to
103	gp130 on any cell and allow for so called IL-6 trans-signaling. ^{15,17} Hence, trans-signaling allows
104	for IL-6 signaling in cells with low or absent IL-6R expression. Recently, it has become evident
105	that trans-signaling is the predominant pathway behind IL-6 mediated pathogenesis. ¹⁸ Also
106	gp130 exists as a soluble version, soluble gp130 (sgp130), produced by proteolytic cleavage as
107	well as alternative splicing. ¹⁹ sgp130 can bind to the IL-6:sIL-6R complex, hindering binding to
108	membrane bound gp130, thereby inhibiting trans-signaling. ¹⁹ In blood, sIL-6 and sgp130 levels
109	are high, and their ratio will determine the IL-6 trans-signaling potential, thereby affecting the
110	potential pathogenic effects of IL-6 in circulation. ¹⁸
111	Endetheliel cells can another high levels of U. Concerctionaletics 20 As and the liel cells

Endothelial cells can produce high levels of IL-6 upon stimulation.²⁰ As endothelial cells express no or very little IL-6R, they *per se* do not seem to respond to the IL-6 they produce.²⁰⁻²³ However, studies have shown that addition of sIL-6R to endothelial cell cultures renders them responsive to IL-6 via trans-signaling.²¹

Here, we sought to investigate the source of IL-6 during hantavirus infection, as well as the possible consequences of IL-6 trans-signaling on infected vascular endothelial cells. We show that endothelial cells produce large amounts of IL-6 upon PUUV infection. Addition of

- sIL-6R to PUUV infected endothelial cells lead to strongly enhanced secretion of IL-6 and CCL2
- and upregulation of ICAM-1 on the cell surface. In addition, we show that sIL-6R led to VE-
- 120 cadherin internalization and increased monolayer permeability in infected endothelial cells.
- 121 Finally, we show that HFRS patients exhibit altered levels of sIL-6R and sgp130, and that this
- 122 correlate to markers of severity, suggesting a direct role for IL-6, via IL-6 trans-signaling, in
- 123 hantavirus pathogenesis.

124 METHODS

125 Patients

- 126 Twenty-eight HFRS patients were included in the study. Patients were diagnosed during the
- 127 years 2006-2014, at the University Hospital of Umeå, Sweden. Twenty uninfected controls
- sampled in 2017 were included as control subjects. Peripheral blood was collected into CPT
- 129 tubes, as described previously.²⁴ Following centrifugation, plasma was retrieved and stored at
- 130 -80°C until analysis. All subjects provided written consent before participation in the study.
- 131 Ethical approval was obtained from the Regional Ethics Committee of Umeå University
- 132 (application number 04-133M).

133The HFRS cohort included 13 females and 15 males with a mean age of 49 years (range

134 18-78 years) and the controls included 7 females and 13 males of a mean age of 50 years (range

135 37-63 years) (Table 1). Samples were collected from the acute phase at a median of 5 days

136 (range 2-7 days) post symptom debut, and from the convalescent phase at a median of 98 days

137 (range 42-494 days) post symptom debut (Table 1).

138

139 Cells and viruses

140 Pooled human umbilical vein endothelial cells (HUVECs) (Lonza) were maintained in

endothelial growth medium (EGM-2) supplemented with EGM-2 endothelial SingleQuots

142 (Lonza) in 5% CO₂ at 37°C. Prior to experiments, hydrocortisone was excluded from the

143 medium. Buffy coats from blood donors were purchased from Karolinska University Hospital

144 (Stockholm, Sweden). Peripheral blood mononuclear cells (PBMCs) were isolated from buffy

145 coats using Lymphoprep (Stemcell Technologies) and maintained in RPMI-1640 medium (GE

146 Healthcare) supplemented with 10% FCS (Sigma-Aldrich) and 2 mM L-glutamine (Life

147 Technologies). PUUV strain CG1820 was propagated on A549 cells and ANDV strain Chile-

¹⁴⁸ 9717869 on Vero E6 cells, as previously described.²⁵

149

150 Infection and treatments

- 151 HUVECs were infected with 200 µl (in 24 well plates) or 1 ml (in 6 well plates) virus diluted in
- 152 HUVEC medium at multiplicity of infection (MOI) 1. Cells were infected for 1 h in 5% CO₂ at
- 153 37°C, with gentle shaking every 10 min. After infection, virus was removed and replaced with 1
- 154 ml fresh medium. At 48 h post infection, medium was replaced with medium containing
- recombinant human IL-6R alpha protein (R&D systems) at different concentrations. Cells
- 156 without sIL-6R treatment and cells treated with 10 ng/ml recombinant IL-6 (rIL-6) (R&D
- systems), in addition to the sIL-6R treatment, were used as controls. After 24 h treatment,
- supernatants were collected and stored at -80°C until analysis.
- PBMCs cultured in 96-well plates (1 million cells in 200 μ l medium) were exposed to PUUV (MOI=3) for 2 h in 5% CO₂ at 37°C. After infection, virus was removed and replaced with fresh medium. Supernatants were collected after a centrifugation step and stored at -80°C until analysis.
- 163

164 Flow cytometric analyses

- 165 HUVECs were detached using Accutase (Thermo Fisher Scientific) and then used for flow
- 166 cytometry. HUVECs were stained with anti-ICAM-1 antibody conjugated with PE-Vio770
- 167 (Milteny Biotec) for 20 min at room temperature (RT). Live/Dead Aqua (Invitrogen) was used
- 168 for the identification of dead cells. Cells were fixed for 30 min using Transcription Factor

169	Staining Buffer Set (BD Biosciences). Samples were acquired on a BD LSR Fortessa instrument
170	(BD Biosciences). Data were analyzed using FlowJo version 10.4.

171

- 172 ELISA
- 173 Prior to ELISA, plasma samples were diluted in ready-to-use ELISA diluent (Mabtech); 1:2 for
- 174 IL-6 and IL-6/sIL-6R complex and 1:400 for sIL-6R and sgp130 ELISAs. Levels of IL-6 were
- analyzed using ELISA development kit (Mabtech) and levels of sIL-6R, IL-6:IL-6R complex,
- and sgp130 were analyzed using DuoSet ELISA kits (R&D), all according to the manufacturer's
- 177 guidelines.
- 178

179 Immunofluorescence

HUVECs cultured on glass cover slips were fixed with pre-warmed 4% paraformaldehyde for 15 min at RT. Cells were then permeabilized using 0.5% Triton X for 5 min at RT, washed three

times and blocked with 0.5% BSA in PBS for 30 min at RT. Cover slips were incubated with

primary antibody for 1 h at RT, washed in PBS three times and then incubated with secondary

- 184 antibody for 1 h at RT. VE-cadherin expression was detected using anti-VE-cadherin
- 185 monoclonal antibody (Cell Signaling Technology) and goat anti-rabbit IgG AF488 (Life
- 186 Technologies). PUUV proteins were detected using polyclonal antibodies from convalescent

187 patient serum for 1 h at RT and goat anti-human IgG AF647 (Life Technologies). Nuclei were

stained using DAPI (Life Technologies). Washed cover slips were mounted onto glass slides

- using ProLong Gold Antifade Mountant (Thermo Fisher Scientific). Cells were examined by
- immunofluorescence confocal microscopy at 60X magnification. Images were analyzed using
- 191 ImageJ.

192 Transendothelial electrical resistance (TEER)

193	HUVECs, uninfected or infected with PUUV for 24 h, were split onto HTS Transwell 24-well
194	plates with 0.4 μ m pore and 6.5 mm inserts (Corning) at a density of 1x10 ⁵ cells in 100 μ l per
195	well. To the lower compartment, 600 μl medium was added. Cells were cultured at 37°C for 24 h
196	and then treated with sIL-6R. The transendothelial electrical resistance (TEER) was measured
197	after 24 h using an EVOM2 epithelial voltohmmeter (World precision instruments), according to
198	the manufacturer's guidelines. The mean TEER of three measurements/well was used to
199	calculate the TEER/cm2.
200	
201	Statistical analyses
202	Statistical analyses were performed using Graph Pad Prism v.9. Paired comparisons within
203	HFRS patients were performed using Wilcoxon test. Comparisons between controls and acute
204	and convalescent HFRS patients were performed using Kruskal-Wallis test followed by Dunn's
205	multiple comparison test. Comparisons between in vitro conditions were performed using two-
206	way ANOVA followed by Dunnet's or Šídák's multiple comparison test. Spearman's rank
207	correlation coefficient was used for examining correlations.

208 **RESULTS**

209 PUUV-infected cells demonstrate potent IL-6 secretion

- 210 To investigate possible sources of IL-6 production during hantavirus infection, we assessed IL-6
- 211 secretion from HUVECs and PBMCs. HUVECs were infected with PUUV at MOI 1 and
- supernatants were collected at 24, 48, and 72 h post infection. Infected HUVECs produced
- higher levels of IL-6 than uninfected HUVECs at 48 and 72 h post infection (Figure 1A).
- PBMCs were exposed to PUUV at MOI 3 and supernatants were collected after 24, 48, and 72 h.
- 215 At 48 h post PUUV-exposure, PBMCs produced higher levels of IL-6 compared to unexposed
- 216 PBMCs, albeit at lower concentrations than HUVECs (Figure 1B). Next, we examined the
- 217 concentrations of sgp130 in the supernatants. In infected HUVECs, the levels of sgp130 were
- significantly increased at 72 h post infection (Figure 1C). In supernatants of PUUV-exposed
- 219 PBMCs, no such increase was observed (Figure 1D). In the PBMC supernatants, also sIL-6R
- 220 levels were analyzed. No significant increase in sIL-6R levels was observed in PUUV-exposed
- 221 compared to unexposed PBMCs (Figure 1D). Together, these data show that PUUV induces
- strong IL-6 secretion in HUVECs and PBMCs, and that this coincides with increased production
- of sgp130 in HUVECs.



Fig. 1. PUUV-infected cells secrete IL-6. HUVECs were infected with PUUV (MOI=1) and

PBMCs were exposed to PUUV (MOI=3) for 24-72 h. Supernatants were assessed for IL-6,

- soluble gp130 (sgp130), and soluble IL-6R (sIL-6R) using ELISA. (A) Levels of IL-6 in
- supernatants of HUVECs (n=3) and (B) PBMCs (24-48 h, n=6, 72 h, n=2). (C) sgp130 levels in
- supernatants of HUVECs (n=3). (D) Levels of sgp130 (n=2) and sIL-6R (n=7) in PBMC
- supernatants. Two-way ANOVA followed by Šídák's multiple comparison test. *, p<0.05, **,

231 p<0.01.

232

224

233 IL-6 trans-signaling in PUUV-infected cells drives inflammation

- Having shown that HUVECs produce high levels of IL-6 upon PUUV infection, we next
- 235 investigated potential autocrine effects of IL-6 trans-signaling on endothelial cells. IL-6 trans-
- signaling in endothelial cells has been shown to increase secretion of IL-6,²¹ and CCL2.^{22,24} As

237	endothelial cells have been reported to be unresponsive to IL-6 treatment, ²¹ inflammatory
238	responses downstream of IL-6 were assessed after addition of recombinant sIL-6R to the cell
239	cultures. At 48 h post infection, HUVEC medium was exchanged to fresh medium with or
240	without different concentrations of sIL-6R. After 24 h of treatment, IL-6 and CCL2 levels in
241	supernatants were determined by ELISA. Levels of IL-6 and CCL2 in supernatants were
242	increased in infected HUVECs treated with sIL-6R, in a dose-dependent manner (Figure 2A-B).
243	As expected, ^{22,26} increased CCL2 secretion was also observed in uninfected HUVECs treated
244	with recombinant IL-6 (rIL-6) along with the sIL-6R treatment (Figure S1A).
245	IL-6 signaling has been reported to increase the cell surface expression of ICAM-1 on
246	endothelial cells. ²⁶⁻²⁹ Thus, ICAM-1 expression on HUVECs was assessed by flow cytometry.
247	As previously observed for Hantaan orthohantavirus (HTNV) infected cells, ^{30,31} increased
248	ICAM-1 expression was observed on PUUV-infected compared to uninfected HUVECs (Figure
249	2C-D). Addition of sIL-6R to the cultures further increased the ICAM-1 expression on infected,
250	but not uninfected cells, in a dose-dependent manner (Figure 2C-D). Together, these data
251	indicate that endogenously produced IL-6 from PUUV-infected endothelial cells, in presence of
252	sIL-6R, stimulate IL-6 trans-signaling in an autocrine manner that fuels the inflammatory
253	responses by causing endothelial cell activation and increased secretion of IL-6 and CCL2.







Levels of IL-6 in supernatants were also increased in ANDV-infected HUVECs treated with sIL-6R (Figure S2), suggesting this is a common feature of HFRS and HPS-causing hantaviruses.

269

270 PUUV-mediated IL-6 trans-signaling disrupts endothelial cell barrier functions

271 To further investigate the functional consequences of IL-6 trans-signaling, we sought to evaluate the barrier function in infected HUVEC monolayers. For this purpose, we first examined the 272 expression of VE-cadherin in infected and uninfected cells, with or without sIL-6R, using 273 immunofluorescence microscopy. In uninfected untreated cells, solid VE-cadherin junctions and 274 intact cell monolayers were observed (Figure 3A). Addition of sIL-6R to uninfected cells had no 275 clear effect on the VE-cadherin organization nor the cell integrity (Figure 3A). In contrast, 276 internalization of VE-cadherin was seen in PUUV-infected HUVECs without sIL-6R treatment 277 (Figure 3A). sIL-6R treatment of infected cells caused further downmodulation of VE-cadherin 278 279 from the cell surface (Figure 3A). Interestingly, while the cell monolayer appeared to be intact in untreated PUUV-infected cells, sIL-6R treatment caused gap formation in the cell monolayer, 280 indicating that the barrier function was severely disrupted (Figure 3A). As expected, a similar 281 282 phenotype was observed when uninfected cells were treated with rIL-6 in addition to the sIL-6R treatment (Figure S1B), showing that this indeed was dependent on IL-6 trans-signaling. 283 284 To further examine the endothelial cell barrier function upon sIL-6R treatment, we 285 analyzed the transendothelial electrical resistance (TEER) in PUUV-infected and uninfected HUVECs. PUUV infection alone caused decreased TEER compared to uninfected cells (Figure 286 3B). PUUV infection together with sIL-6R treatment further caused a dose-dependent loss of 287 288 barrier function 24 h post treatment, as indicated by decreased TEER compared to uninfected

- 289 HUVECs and PUUV-infected untreated cells (Figure 3B). Similarly, a dose-dependent decrease
- in TEER was observed when uninfected cells were treated with rIL-6 + sIL-6R (Figure 3B).
- 291 Supporting previous reports,^{32,33} rIL-6 treatment alone did not affect the monolayer permeability
- in uninfected HUVECs (Figure 3B). Collectively, these data indicate that IL-6 produced by
- 293 PUUV-infected endothelial cells in an IL-6 trans-signaling dependent manner enhances VE-
- 294 cadherin disorganization and loss of endothelial cell monolayer integrity.



295

Fig. 3. IL-6 trans-signaling disrupts endothelial cell barrier functions during hantavirus

297 infection. Uninfected and infected HUVECs were treated with sIL-6R at the concentrations

- 298 31.25, 62.5, 125, 250, or 500 ng/ml for 24 h or left untreated. (A) Immunofluorescence images
- showing expression of DAPI (blue), virus (red), and VE-cadherin (green). Representative
- 300 images of three independent experiments are shown. (B) Transendothelial electrical resistance of

301	uninfected (white symbol) and infected HUVECs (black symbol), with and without sIL-6R.
302	Uninfected HUVECs treated with rIL-6 in addition to sIL-6R were used as control (grey
303	symbol). Symbols depict mean and error bars indicate SD. Two-way ANOVA followed by
304	Dunnet's or Šídák's multiple comparison test. Black asterisks indicate significance when
305	comparing PUUV to uninfected. Red asterisks indicate significance when comparing each sIL-
306	6R-treated conditions of PUUV-infected cells with untreated PUUV-infected cells. *, p<0.05;
307	**, p<0.01; ***, p<0.001, ****, p<0.0001.

308

309 The plasma sIL-6R/gp130 ratio is increased during acute HFRS

310 Given the pronounced effects of IL-6 trans-signaling observed in hantavirus infected cells in

311 *vitro*, we next sought to evaluate the levels of soluble IL-6 receptors in HFRS patients. The

312 physiological effects of IL-6 largely depend on the levels of sIL-6R and sgp130 in

313 circulation.^{15,18} Although increased systemic IL-6 levels have been repeatedly reported in HFRS

and HPS patients,^{7-9,11,12} the concentrations of sIL-6R and sgp130 have not yet been

comprehensively studied in hantavirus-infected patients. Thus, we analyzed the levels of IL-6,

sIL-6R, IL-6:sIL-6R complex, and sgp130 in plasma of 28 PUUV-infected HFRS patients,

during acute and convalescent phase, as well as in 20 uninfected controls. The HFRS patients

displayed typical symptoms for HFRS, showing thrombocytopenia, and elevated levels of

319 creatinine and CRP (Table 1). Information regarding complications (thrombosis, severe

bleeding) as well as information on medical interventions including administration of

321 intravenous fluid, oxygen treatment, and platelet transfusion are presented in Table 1. IL-6 levels

322 were, as previously reported,^{8,11} increased in acute HFRS (Figure 4A). Levels of sIL-6R were

higher during acute, compared to the convalescent, HFRS, and similar to that observed in



333



Fig. 4. The plasma sIL-6R/sgp130 ratio is increased during acute HFRS and IL-6 transsignaling potential correlate to severity. Plasma levels of (A) IL-6, (B) sIL-6R, (C) IL-6:sIL-

(n=28). (E) Ratio of plasma sIL-6R and sgp130 in controls and HFRS patients (n=27). (F)Correlation between sgp130 levels and number of interventions during acute HFRS (n=28). (G)
Correlation between sgp130 levels and serum albumin (n=13). (H) Plasma sIL-6R/sgp130 ratio
in patients with or without oxygen treatment (median, interquartile range). Wilcoxon test;
Kruskal-Wallis test; median. Spearman's rank correlation coefficient. *, p<0.05; **, p<0.01; ***,
p<0.001, ****, p<0.0001.

344

345 Sgp130 level and IL-6 trans-signaling potential correlate to disease severity

We finally analyzed for possible correlations of IL-6 signaling factors, including IL-6 trans-346 signaling potential, and severity of HFRS. This revealed that sgp130 levels were inversely 347 correlated with the number of interventions in patients (Figure 4F), suggesting that patients with 348 a more complicated disease had the lowest sgp130 levels. Furthermore, sgp130 levels positively 349 correlated with serum albumin levels (Figure 4G), indicating that decreased sgp130 levels 350 coincide with loss of serum albumin, which is indicative of increased vascular permeability. The 351 sIL-6R/sgp130 ratio was significantly higher in patients receiving oxygen treatment (Figure 4H). 352 Together, this suggest low sgp130 levels and high IL-6 trans-signaling potential is associated 353 354 with severe HFRS.

355 **DISCUSSION**

356	HFRS and HPS are characterized by strong inflammatory responses and vascular
357	permeability. ^{2,3,7-11} Despite significant morbidity and mortality in hantavirus-infected
358	individuals, no specific treatments are available. Importantly, the mechanisms driving
359	hantavirus-mediated pathogenesis are not known, hampering development of specific
360	therapeutics. IL-6 has been highlighted as an important cytokine in hantavirus infections, as it is
361	associated with HFRS and HPS disease severity. ^{7,12,13} However, the potential role for IL-6 in the
362	pathophysiology of hantavirus diseases is unknown. Here, we report IL-6 trans-signaling as a
363	potential mechanism behind IL-6-mediated pathology during hantavirus infections.
364	We observed that PUUV infection stimulates IL-6 secretion in HUVECs and PBMCs. IL-
365	6 secretion has previously been reported in cells infected with ANDV, HTNV, and Prospect Hill
366	orthohantavirus. ^{34,35} When studying IL-6 signaling <i>in vitro</i> , it is important to consider the
367	receptor availability on the cells of the model system. While gp130 is expressed by all cells, IL-
368	6R is mainly expressed by hepatocytes and certain immune cells. ¹⁴ Endothelial cells express no
369	or very little IL-6R, and therefore display no or limited responses to IL-6 per se. ^{20,21,36} This may
370	explain why a previous study did not observe any effect upon IL-6 treatment of hantavirus
371	infected cells. ³² However, treatment of endothelial cells with IL-6 in combination with sIL-6R
372	leads to IL-6 trans-signaling. IL-6 trans-signaling in endothelial cells has been shown to cause
373	secretion of IL-6 and CCL2 as well as upregulation of ICAM-1 on the cell surface. ^{21,22,26-29} Here,
374	we recapitulated these findings in a PUUV-infection model. Using this model, we showed that
375	PUUV-induced endogenous IL-6, in presence of sIL-6R, activated endothelial cells in an
376	autocrine manner. This activation caused upregulation of the adhesion molecule ICAM-1,
377	indicating enhanced activation of the endothelial cells. This is in line with the increased plasma
378	levels of soluble ICAM-1, VCAM-1, E-selectin, and syndecan-1 observed in HFRS patients. ³⁷

PUUV-mediated IL-6 trans-signaling further promoted a pro-inflammatory loop with augmented secretion of IL-6 and CCL2. CCL2 is a known chemoattractant for T cells and myeloid cells.^{38,39} Apart from its chemoattracting function, CCL2 also mediates attachment to vascular endothelial cells and trans-endothelial migration of T cells and myeloid cells.³⁸⁻⁴⁰ Together, these data suggest that infected endothelial cells may, via IL-6 trans-signaling, constitute important drivers of IL-6 production and inflammation in HFRS/HPS patients.

Vascular permeability is a common hallmark of hantavirus infections.^{2,3} The mechanism 385 behind why hantavirus infection leads to massively increased vascular permeability, including 386 the life-threatening pulmonary dysfunction observed in HPS, is largely unknown.³ Here, we 387 demonstrated that sIL-6R treatment of infected endothelial cells increases VE-cadherin 388 disorganization and barrier permeability. This is in line with previous reports showing VE-389 cadherin internalization and increased permeability of endothelial cells treated with IL-6 in 390 combination with sIL-6R.^{28,33,41} Remarkably, PUUV infection alone, without sIL-6R treatment, 391 392 caused some VE-cadherin internalization and decreased monolayer integrity. Previously, a VEGF/VEGFR2-dependent internalization of VE-cadherin has been described in ANDV and 393 HTNV infected endothelial cells.^{42,43} Such a VEGF-dependent mechanism could possibly 394 395 explain the VE-cadherin disorganization and decreased membrane integrity seen in untreated PUUV-infected HUVECs. Taken together, these findings indicate that hantavirus infection alone 396 397 to some extent modulates the endothelial cell barrier integrity, and that subsequent IL-6 trans-398 signaling further aggravates this, leading to a severe loss of barrier function.

The *in vivo* effects of IL-6 depend on the complex interactions of IL-6 with sIL-6R and sgp130, which constitute a buffer system that regulates the half-life and signaling of IL-6.^{15,18} While it is well-established that IL-6 levels are increased in HFRS and HPS patients, peripheral

levels of sIL-6R and sgp130 have not been extensively studied in hantavirus infected patients. 402 Here, plasma sIL-6R levels were found to be elevated during the acute, compared to the 403 convalescent, phase of HFRS. Intriguingly, compared to controls, lower plasma sgp130 404 concentration was observed both during acute and convalescent HFRS. As sgp130 can inhibit IL-405 6 trans-signaling,¹⁹ a decrease in sgp130 may have pathogenic consequences. In support of this 406 notion, decreased sgp130 levels have been described in patients with type 2-diabetes,⁴⁴ and in 407 patients with coronary artery disease.⁴⁵⁻⁴⁷ Furthermore, increased sgp130 levels have been 408 associated with decreased odds of myocardial infarction.⁴⁸ The inverse correlation found 409 410 between plasma sgp130 and number of interventions during acute HFRS may indicate that patients with low sgp130 levels also have more severe symptoms. Albumin has been suggested 411 as a marker of vascular permeability.⁴⁹ Thus, the positive correlation between sgp130 levels and 412 serum albumin levels during acute HFRS may suggest a link between low sgp130 levels and 413 increased vascular leakage. Interestingly, in patients with coronavirus disease 2019 (COVID-19), 414 low levels of serum albumin have been associated with more severe pulmonary symptoms.⁵⁰ 415 Analyses of IL-6 receptor levels and of possible correlations to risk for severe and fatal outcome 416 in HPS patients could help decipher the role of IL-6 trans-signaling in hantavirus-induced 417 418 pathogenesis, as these patients in general are more severely ill than HFRS patients. The skewed IL-6-receptor balance during acute HFRS, as indicated by the increased sIL-419 420 6R/sgp130 ratio, suggests an increased potential of IL-6-trans-signaling in patients. Importantly, 421 while classical signaling via membrane-bound IL-6R mainly seems to have homeostatic, protective, effects, trans-signaling has recently emerged as the driver of IL-6 mediated 422 pathogenesis.¹⁸ In most HFRS patients, plasma IL-6 levels are not as strongly elevated as 423 424 observed in HPS patients. Given the capacity of endothelial cells to produce large amounts of IL-

425	6, it is possible that the concentration of IL-6 is higher at local sites of infection than
426	systemically. It is further possible that highly vascularized sites, such as the lungs, have very
427	high local concentrations of infected endothelial cell-derived IL-6, and as a consequence are
428	more exposed to IL-6 trans-signaling. This scenario is consistent with the observations that lungs
429	are heavily affected during HPS, and that almost all lung endothelial cells are infected in some
430	patients. ⁵¹⁻⁵³ Altogether, our data suggest altered concentrations of sIL-6R and sgp130 during
431	hantavirus-infection, which may increase the likelihood of IL-6 trans-signaling in infected
432	endothelial cells and increased vascular permeability as a consequence.
433	Treatment strategies targeting IL-6 signaling have proven successful in for example
434	rheumatoid arthritis and for treatment of COVID-19.18,54,55 Further studies investigating the role
435	of IL-6 in the pathogenesis of HFRS and HPS will be valuable for the assessment of the
436	relevance of IL-6-targeting therapeutics in severe hantavirus infections. In conclusion, we show
437	that PUUV-infected endothelial cells produce IL-6 that, in an IL-6 trans-signaling dependent
438	manner, strongly affect infected endothelial cell functions. We further show a correlation
439	between IL-6 trans-signaling potential and severity in HFRS patients. These findings suggest that
440	IL-6 trans-signaling may represent a treatable target in HPS and severe HFRS.

441 Data sharing

442 All data are available in the main text or the supplementary materials.

443

444 Acknowledgements

- 445 We thank the patients and volunteers who contributed with clinical material to this study. C.
- 446 Ahlm received fundings from Region Västerbotten and Umeå University, project numbers RV-
- 579011, RV-734361, and RV-965866, and from the Heart-Lung Foundation, project numbers
- 448 20170334 and 20150752. J. Klingström received fundings from the Swedish Research Council,
- 449 project number 2018-02646, and from the center for medical innovation (CIMED), project
- 450 number 2020-0141.
- The funders played no role in the design of the study, data collection, data analysis, interpretation
- 452 of results or writing of the paper.
- 453

454 **Declaration of interests**

455 Authors declare that they have no competing interests.

- 457 **Author contributions**
- 458 Conceptualization: KTM, JK
- 459 Methodology: KTM, LN, WC, JK
- 460 Investigation: KTM, LN, WC, TT, CA
- 461 Analyzed data: KTM
- 462 Validated data: KTM, LN
- 463 Visualization: KTM

- 464 Funding acquisition: CA, JK
- 465 Project Administration: KTM, JK
- 466 Resources: JWB, TT, CA
- 467 Supervision: KTM, JK
- 468 Writing original draft: KTM, JK
- 469 Writing review & editing: KTM, LN, WC, JWB, TT, CA, JK

References

Bradfute SB, Calisher CH, Klempa B, Klingström J, Kuhn JH, Laenen L, et al. ICTV virus taxonomy profile: Hantaviridae 2024. J Gen Virol. 2024;105:001975. Klingström J, Smed-Sörensen A, Maleki KT, Solà-Riera C, Ahlm C, Björkström NK, et al. Innate and adaptive immune responses against human Puumala virus infection: immunopathogenesis and suggestions for novel treatment strategies for severe hantavirus-associated syndromes. J Inter. Med. 2019;285:510-523. Vial PA, Ferrés M, Vial C, Klingström J, Ahlm C, López R, et al. Hantavirus in humans: a review of clinical aspects and management. Lancet Infect Dis. 2023;23:e371-e382. Rasmuson J, Lindqvist P, Sörensen K, Hedström H, Blomberg A, Ahlm C. Cardiopulmonary involvement in Puumala hantavirus infection. BMC Infect Dis. 2013;13:501. Solà-Riera C, Gupta S, Ljunggren H-G, Klingström J. Orthohantaviruses belonging to three phylogroups all inhibit apoptosis in infected target cells. Sci Rep. 2019;9:834. Solà-Riera C, García M, Ljunggren H-G, Klingström J. Hantavirus inhibits apoptosis by preventing mitochondrial membrane potential loss through up-regulation of the pro-survival factor BCL-2. PLoS Pathog. 2020;16:e1008297. Maleki KT, García M, Iglesias A, Alonso D, Ciancaglini M, Hammar U, et al. Serum markers associated with severity and outcome of hantavirus pulmonary syndrome. J Infect Dis. 2019;219:1832–1840. Linderholm M, Ahlm C, Settergren B, Waage A., Tärnvik A. Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. J Infect Dis. 1996;173:38-43. Morzunov SP, Khaiboullina SF, St Jeor S, Rizvanov AA, Lombardi VC. Multiplex analysis of serum cytokines in humans with hantavirus pulmonary syndrome. Front Immunol.2015;6:432. Saksida A, Wraber B, Avšič-Županc T. Serum levels of inflammatory and regulatory cytokines in patients with hemorrhagic fever with renal syndrome. BMC Infect Dis. 2011;11:142. Sadeghi M, Eckerle I, Daniel V, Burkhardt U, Opelz G, Schnitzler P. Cytokine expression during early and late phase of acute Puumala hantavirus infection. BMC Immunol. 2011;12:65. Angulo J, Martínez-Valdebenito C, Marco C, Galeno H, Villagra E, Vera L et al. Serum levels of interleukin-6 are linked to the severity of the disease caused by Andes Virus. PLoS Negl Trop Dis. 2017;11:e0005757.

Outinen TK, Mäkelä SM, Ala-Houhala IO, Huhtala HS, Hurme M, Paakkala AS, et al. The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations. BMC Infect Dis. 2010;10:132. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16:448-457. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J Biol Sci. 2012;8:1237-1247. Mülberg J, Schooltink H, Stoyan T, Günther M, Graeve L, Buse G, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993;23:473-480. Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, et al. The balance of interleukin (IL)-6, IL-6 soluble IL-6 receptor (sIL-6R), and IL-6 sIL-6R sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem. 2018;293:6762-6775. Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller T. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol. 2023;23:666-681. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. *Blood* 1993;82:1120–1126. Podor TJ, Jirik FR, Loskutoff DJ, Carson DA, Lotz M. Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann N Y Acad Sci. 1989;557:374–387. Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest. 1997;100:2752-2756. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-325. Montgomery A, Tam F, Gursche C, Cheneval C, Besler K, Enns W, et al. Overlapping and distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells. Am J Physiol Cell Physiol. 2021;320:C554–C565. Scholz S, Baharom F, Rankin G, Maleki KT, Gupta S, et al. Human hantavirus infection elicits pronounced redistribution of mononuclear phagocytes in peripheral blood and airways. *PLoS Pathog.* 2017;13:e1006462. Stoltz M, Ahlm C, Lundkvist Å, Klingström J. Lambda interferon (IFN-lambda) in serum is decreased in hantavirus-infected patients, and in vitro-established infection is insensitive to treatment with all IFNs and inhibits IFN-gamma-induced nitric oxide production. J Virol. 2007;81:8685-8691.

559 26 Suzuki M, Hashizume M, Yoshida H, Mihara M. Anti-inflammatory mechanism of 560 tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and 561 adhesion molecule. *Rheumatol Int.* 2009;30:309.

- 563 27 Watson C, Whittaker S, Smith N, Vora AJ, Dumonde DC, Brown KA. IL-6 acts on 564 endothelial cells to preferentially increase their adherence for lymphocytes. *Clin Exp Immunol*. 565 1996;105:112–119.
- Valle ML, Dworshak J, Sharma A, Ibrahim AS, Al-Shabrawey M, Sharma S. Inhibition of
 interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal
 endothelial cells. *Exp Eye Res.* 2019;178:27–36.
- 570

562

566

- Wung BS, Ni CW, Wang DL. ICAM-1 induction by TNFalpha and IL-6 is mediated by
 distinct pathways via Rac in endothelial cells. *J Biomed Sci.* 2005;12:91–101.
- 574 30 Björkström NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, et al. Rapid 575 expansion and long-term persistence of elevated NK cell numbers in humans infected with 576 hantavirus. *J Exp Med*. 2011;208:13–21.
- 578 31 Yu H., Jiang W, Du H, Xing Y, Bai G, Zhang Y, et al. Involvement of the Akt/NF-κB
 579 pathways in the HTNV-mediated increase of IL-6, CCL5, ICAM-1, and VCAM-1 in HUVECs.
 580 *PloS One* 2014;9:e93810.
- 581

577

Niikura M, Maeda A, Ikegami T, Saijo M, Kurane I. Morikawa S. Modification of
endothelial cell functions by Hantaan virus infection: prolonged hyper-permeability induced by
TNF-alpha of hantaan virus-infected endothelial cell monolayers. *Arch Virol.* 2004:149, 1279–
1292.

Alsaffar H, Martino N, Garrett JP, Adam AP. Interleukin-6 promotes a sustained loss of
 endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo
 protein synthesis. *Am J Physiol Cell Physiol*. 2018;314:C589–C602.

- Jiang H., Wang PZ, Zhang Y, Xu Z, Sun L, Wang LM, et al. Hantaan virus induces tolllike receptor 4 expression, leading to enhanced production of beta interferon, interleukin-6 and tumor necrosis factor-alpha. *Virology* 2008;380:52–59.
- 594
 595 35 Khaiboullina SF, Morzunov SP, St Jeor SC, Rizvanov AA, Lombardi VC. Hantavirus
 596 infection suppresses thrombospondin-1 expression in cultured endothelial cells in a strain-specific
 597 manner. *Front Microbiol.* 2016;7:1077.
- 598

590

Montgomery A, Tam F, Gursche C, Cheneval C, Besler K, Enns W, et al. Overlapping and
distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells. *Am J Physiol Cell Physiol.* 2021;320:C554–C565.

60337Connolly-Andersen A-M, Thunberg T, Ahlm C. Endothelial activation and repair during604hantavirus infection: association with disease outcome. Open Forum Infect Dis. 2014;1:ofu027.

Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA. 1994;91:3652-3656. Gschwandtner M, Derler R, Midwood KS. More than just attractive: How CCL2 influences myeloid cell behavior beyond chemotaxis. Front Immunol. 2019;10:2759. Lee CH, Zhang HH, Singh SP, Koo L, Kabat J, Tsang H, et al. C/EBPδ drives interactions between human MAIT cells and endothelial cells that are important for extravasation. eLife 2018;7:e32532. Lo C-W, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al., IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011;71:424-434. Gorbunova E., Gavrilovskaya IN, Mackow ER. Pathogenic hantaviruses Andes virus and Hantaan virus induce adherens junction disassembly by directing vascular endothelial cadherin internalization in human endothelial cells. J Virol. 2010;84:7405-7411. Shrivastava-Ranjan P. Rollin PE, Spiropoulou CF. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J Virol. 2010;84:11227–11234. Aparicio-Siegmund S, Garbers Y, Flynn CM, Waetzig GH, Gouni-Berthold I, Krone W, et al. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2019;317:E411–E420. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32:281–290. Cui Y, Dai W, Li Y. Circulating levels of sgp130 and sex hormones in male patients with coronary atherosclerotic disease. Atherosclerosis 2017;266:151-157. Korotaeva AA, Samoilova EV, Chepurnova DA, Zhitareva IV, Shuvalova YA, Prokazova NV. Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis. Biomarkers 2018;23:527–532. Moreno Velásquez I, Golabkesh Z, Källberg H, Leander K, de Faire U, Gigante B. Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction. Atherosclerosis 2015:240:477-481. Vandoorne K, Addadi Y, Neeman M. Visualizing vascular permeability and lymphatic drainage using labeled serum albumin. Angiogenesis 2010;13:75-85.

50 Wu MA, Fossali T, Pandolfi L, Carsana L, Ottolina D, Frangipane V, et al.
Hypoalbuminemia in COVID-19: assessing the hypothesis for underlying pulmonary capillary
leakage. *J Intern Med.* 2021;289:861–872.

- 51 Nolte KB, Feddersen RM, Foucar K, Zaki SR, Koster FT, Madar D, et al. Hantavirus
 pulmonary syndrome in the United States: a pathological description of a disease caused by a new
 agent. *Hum Pathol.* 1995;26:110–120.
- Boroja M., Barrie JR, Raymond GS. Radiographic findings in 20 patients with hantavirus
 pulmonary syndrome correlated with clinical outcome. *Am J Roentgenol*. 2002;178:159–163.
- 53 Duchin JS, Koster FT, Peters CJ, Simpson GL, Tempest B, Zaki SR, et al. Hantavirus
 pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. *N Engl J Med.* 1994;330:949–955.
- 663

652

- 54 Tanaka T, Narazaki M, Ogata A, Kishimoto T, A new era for the treatment of inflammatory
 autoimmune diseases by interleukin-6 blockade strategy. *Semin Immunol.* 2014;26:88–96.
- 666
- 667 55 The REMAP-CAP Investigators, Interleukin-6 receptor antagonists in critically ill patients 668 with Covid-19. *N Engl J Med.* 2021;384:1491–1502.

669 **Table 1. Patient characteristics and clinical data.**

Parameter	Controls	HFRS 1 Acute phase	oatients Conv. phase
No. of patients	20	28	
Gender (female/male)	nder (female/male) 7/13 13/15		/15
Age (years), mean (range)	50 (37-63)	49 (18-78)	
Days post symptoms debut, median (range)	NA	5 (2-7)	63 (42-494)
WBC count (x10 ⁹ /L), mean \pm SD*	n.d.	$8{\cdot}9\pm5{\cdot}3$	$7{\boldsymbol{\cdot}}1\pm 2{\boldsymbol{\cdot}}5$
Platelet count (x10 ⁹ /L), mean \pm SD [#]	n.d.	91 ± 49	276 ± 46
Serum creatinine (μ mol/L), mean \pm SD§	n.d.	204 ± 150	87 ± 41
CRP (mg/L), mean \pm SD ^{ε}	n.d.	75 ± 47^{a}	4 ± 3^{b}
Serum albumin (g/L), mean \pm SD [†]	n.d.	$32\pm5{\cdot}8^{c}$	$42\pm3\boldsymbol{\cdot}5^d$
Intravenous fluid, no. of patients (%)	NA	19/28 (68)	NA
Platelet transfusion, no. of patients (%)	NA	3/28 (10)	NA
Oxygen treatment, no. of patients (%)	NA	8/28 (29)	NA
Severe bleeding, no. of patients (%)	NA	4/28 (14)	NA
Thrombosis, no. of patients (%)	NA	4/28 (14)	NA

670

Abbreviations: HFRS, hemorrhagic fever with renal syndrome; NA, not applicable; WBC, white

blood cell; n.d., not done; CRP, C-reactive protein.

673 *WBC; normal range, $3.5-8.8 \times 10^{9}$ /L.

[#]Platelet count; normal range, $165-387 \times 10^9$ /L for women, $145-348 \times 10^9$ /L for men.

⁶⁷⁵ [§]Serum creatinine; reference value <90 μmol/L for women, <105 μmol/L for men.

676 $^{\text{e}}$ CRP; reference value <3 mg/L.

⁶⁷⁷ [†]Serum albumin; normal range 34-54 g/L.

- 678 ^an=26.
- 679 ${}^{b}n=25.$
- $^{c}n=13.$
- 681 $^{d}n=9.$
- 682